MedTrace Logo

Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

NCT03714568 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-12-11

No results posted yet for this study

Summary

To study the single dose and multi-doses pharmacokinetic characteristics and tolerance of TQ-A3326 in the human body；To study the transformation of TQ-A3326；To study the effect of the food on the pharmacokinetic characteristics of TQ-A3326.

Conditions

  • Pharmacokinetic

Interventions

DRUG

TQ-A3326

TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）

DRUG

placebo

Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-11
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714568 on ClinicalTrials.gov